Kanamycin
Paul G. Auwaerter, M.D.
,
Kathryn Dzintars, Pharm.D., BCPS
Pediatric Dosing Author:
Bethany Sharpless Chalk, Pharm.D., BCPPS
INDICATIONS
INDICATIONS
INDICATIONS
FDA
FDA
FDA
Short-term treatment of infections caused by
E. coli
,
Proteus species
(indole-positive and indole-negative),
Enterobacter aerogenes
,
Klebsiella pneumoniae
,
Serratia marcescens
, and
Acinetobacter
species
.
Note: other aminoglycosides, including
gentamicin
,
tobramycin
, and/or
amikacin,
are preferred in this setting.
Staphylococcal infections
(not drug of choice)
Hepatic encephalopathy (oral formulation, no longer available in the U.S.)
Bowel decontamination (oral formulation, no longer available in the U.S.)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
NON-FDA APPROVED USES
Treatment of multi-drug resistant
Mycobacterium tuberculosis
(previously second line)
Non-tubercular mycobacterial (NTM) infections
Gonorrhea
Urinary tract infections
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2025 Unbound Medicine, Inc. All rights reserved